Boston Scientific Corporation has signed a definitive agreement to acquire Intera Oncology, a privately held medical device company focused on interventional oncology. The acquisition will enhance Boston Scientific’s offerings in the treatment of liver-dominant metastases, particularly through the Intera 3000 Hepatic Artery Infusion Pump. This pump, which administers chemotherapy directly to the liver, is FDA-approved for treating metastatic colorectal cancer. The acquisition aligns with Boston Scientific’s commitment to providing innovative solutions for liver cancer, a leading cause of cancer-related deaths.
Peter Pattison, president of Interventional Oncology and Embolization at Boston Scientific, emphasized the acquisition's potential to offer more comprehensive cancer treatment solutions. The Intera 3000 pump, the only constant flow implantable pump for HAI therapy approved in the U.S., has demonstrated significant clinical benefits, including improved tumor response, time to progression, and overall survival compared to systemic chemotherapy. The acquisition, expected to close in the first half of 2025, aligns with Boston Scientific's mission to provide innovative medical technologies that address unmet patient needs and improve health outcomes worldwide.
